BK virus infection is a common viral condition that usually causes no symptoms in healthy people, but can become a serious challenge for those who have received organ transplants. After the body’s immune system is weakened by anti-rejection medicines, this usually dormant virus can reactivate and potentially damage a transplanted kidney, requiring careful monitoring and treatment adjustments.

Managing a Hidden Threat After Transplantation

The treatment of BK virus infection focuses primarily on protecting transplanted organs while allowing the body’s own immune system to regain enough strength to fight off the reactivated virus. Most people acquire BK virus during childhood, experiencing symptoms no worse than a mild cold. After that initial infection, the virus remains in the body for life, typically staying dormant in the kidneys and urinary tract without causing any problems. It is estimated that up to 80 percent of adults carry this latent form of the virus without ever knowing it.^[2]

The real challenge emerges after kidney or bone marrow transplantation. Patients who receive transplants must take powerful immunosuppressive medications—also called anti-rejection medicines—to prevent their bodies from attacking and rejecting the new organ. These medications deliberately weaken the immune system, and as a side effect, the BK virus can “wake up” from its dormant state. When this happens, the virus can multiply and potentially cause damage to the transplanted kidney, a condition known as BK virus-associated nephropathy, or BKVAN. This complication affects between 1 and 10 percent of kidney transplant recipients and can lead to loss of the transplanted kidney in up to 80 percent of those who develop the condition if left unaddressed.^[2][3]

Treatment approaches depend on whether the virus is detected early through routine screening or whether symptoms and kidney damage have already appeared. The timing and intensity of intervention can make a significant difference in outcomes. Current treatment strategies include reducing the strength of immunosuppression, using specific medications with potential antiviral effects, and emerging therapies that harness the power of the immune system in new ways.

Standard Treatment: Carefully Adjusting the Immune Balance

The cornerstone of treating BK virus infection remains the reduction of immunosuppressive medication doses. This approach sounds counterintuitive to transplant patients who have been told how crucial these medications are for preventing organ rejection. However, the strategy is based on a careful balancing act: by slightly reducing the immune suppression, doctors allow the patient’s own immune system to become strong enough to fight the virus, while still maintaining enough protection to prevent rejection of the transplanted organ.^[3][4]

When BK virus is detected in the blood—a condition called viremia—or when viral DNA levels reach concerning thresholds, transplant physicians typically begin by lowering the doses of calcineurin inhibitors, which are common anti-rejection drugs such as tacrolimus or cyclosporine. These medications are powerful immune suppressors, and reducing their levels can help the body mount an effective response against the virus. The reduction is done gradually and under close medical supervision, with frequent monitoring of both viral levels and kidney function to ensure the transplant is not being rejected.^[3]

In addition to reducing calcineurin inhibitors, doctors may switch patients to a different class of immunosuppressive drugs called mechanistic target of rapamycin (mTOR) inhibitors, such as sirolimus or everolimus. These medications suppress the immune system through a different pathway and may have some advantage in controlling BK virus replication compared to traditional immunosuppressants. However, the evidence for their effectiveness varies, and the decision to switch medications depends on individual patient factors and the transplant center’s protocols.^[3]

Another medication that has been explored in standard treatment protocols is leflunomide, a drug originally developed to treat autoimmune conditions like rheumatoid arthritis. Leflunomide has both immunosuppressive and antiviral properties, and some transplant centers have used it to treat BK virus infection. The drug works by interfering with viral replication, potentially helping to reduce the amount of virus in the blood and prevent damage to the transplanted kidney. However, its effectiveness remains variable, and it may cause side effects including liver enzyme elevations, gastrointestinal upset, and in some cases, blood count abnormalities that require monitoring.^[3][6]

The duration of treatment depends entirely on how the virus responds. Doctors monitor viral levels in the blood and urine regularly—typically monthly during the first six months after transplant, then every three months until two years post-transplant. Treatment adjustments continue until viral levels decrease to undetectable or very low levels, and kidney function remains stable. This process can take several months, and in some cases, immunosuppression may need to remain at lower levels indefinitely to prevent viral reactivation.^[5]

One important aspect of standard treatment is what doesn’t work. Fluoroquinolone antibiotics, such as ciprofloxacin and levofloxacin, were once thought to have activity against BK virus and were used both for prevention and treatment. However, clinical studies have found that fluoroquinolone prophylaxis and treatment provide no benefit in kidney transplant recipients with BK virus infection. These antibiotics are no longer recommended as a treatment strategy for this condition.^[3]

The side effects of reducing immunosuppression are primarily related to the increased risk of organ rejection. Transplant recipients who have their anti-rejection medications lowered need especially careful monitoring for signs that their immune system is beginning to attack the transplanted kidney. This includes regular blood tests to check kidney function, and in some cases, kidney biopsies to look for microscopic signs of rejection. If rejection does occur, doctors must balance treating the rejection with managing the ongoing viral infection—a complex clinical challenge that requires expertise and individualized care.

Intensive Screening: Prevention Through Early Detection

One of the most effective strategies for managing BK virus infection is not a drug at all, but rather a systematic approach to monitoring. Intensive screening programs involve testing transplant patients’ blood and urine regularly for the presence of BK virus, then acting quickly when the virus is detected at early stages—before it causes significant kidney damage. This proactive approach has been shown to prevent the loss of transplanted kidneys and reduce the amount of virus in the blood at one year after transplant.^[15]

The screening protocol typically begins one month after transplantation, with monthly testing of blood or urine samples for BK viral DNA using sensitive laboratory techniques called polymerase chain reaction (PCR) tests. These tests can detect even small amounts of virus. Screening continues monthly for the first six months, then every three months until two years post-transplant—the period when BK virus reactivation is most common. When virus is detected in urine (called viruria) or when low levels appear in blood, doctors may preemptively reduce immunosuppression before kidney damage develops.^[5]

The benefit of this intensive screening approach is that it allows treatment to begin when viral levels are still low, before the virus causes BK virus-associated nephropathy—the condition where viral infection damages the kidney tissue itself. Once nephropathy develops, it becomes much harder to treat, and the risk of losing the transplanted kidney increases substantially. Studies have shown that paediatric transplant patients who were screened found that 30 percent had BK viremia and 6.6 percent developed nephropathy within three months post-transplant, highlighting how common and how quickly this condition can develop.^[5]

Treatment Options Being Studied in Clinical Trials

Because there are currently no antiviral drugs proven to be both safe and effective against BK virus, researchers around the world are exploring new treatment approaches in clinical trials. These experimental therapies aim to either directly attack the virus or strengthen the body’s immune response specifically against BK virus without increasing the risk of organ rejection.

Intravenous Immunoglobulin (IVIG)

One of the most promising treatments being studied is intravenous immunoglobulin, commonly abbreviated as IVIG. This therapy involves infusing antibodies collected from thousands of healthy blood donors into the patient’s bloodstream. Because BK virus is so common in the general population, most donor blood contains antibodies against the virus. When concentrated and given to transplant patients, IVIG increases the levels of neutralizing antibodies against the most common BK virus serotypes—different strains of the virus.^[3]

IVIG works by providing passive immunity, meaning the patient receives ready-made antibodies rather than producing their own. These antibodies can bind to the virus particles in the blood and help clear them from the body. The treatment is becoming an increasingly popular option for both treating active BK virus infection and potentially preventing it in high-risk patients. Clinical trials are evaluating optimal dosing schedules, timing of treatment, and which patients are most likely to benefit. IVIG is generally well-tolerated, though side effects can include headache, fever, chills, and rarely, more serious reactions such as kidney damage or blood clots. Because it is a blood product, there is also a theoretical risk of transmitting infections, though modern screening and processing methods have made this extremely rare.^[3]

Cidofovir: Limited by Toxicity

Cidofovir is an antiviral medication that has activity against several DNA viruses, including BK virus. It works by interfering with viral DNA replication, preventing the virus from making copies of itself. In laboratory studies, cidofovir shows promise against BK virus, and some case reports and small clinical studies have suggested potential benefit in transplant patients. However, the major limitation of cidofovir is its significant nephrotoxicity—it can damage the kidneys, which is precisely the organ that transplant teams are trying to protect. This toxic effect on kidney tissue has severely limited the utility and enthusiasm for using cidofovir to treat BK virus-associated nephropathy in kidney transplant recipients.^[3][10]

Some research centers have explored using very low doses of cidofovir or administering it in combination with other medications that might reduce its toxic effects. However, there is no standardized protocol, and the drug remains controversial. In bone marrow transplant patients who develop hemorrhagic cystitis—a painful bladder condition caused by BK virus—cidofovir is sometimes used with more acceptance since the bladder is not the transplanted organ, though kidney toxicity remains a concern.^[10]

Virus-Specific T Cell Therapy: The Future of Treatment

Perhaps the most exciting and innovative approach being developed in clinical trials is virus-specific T cell therapy. This treatment represents a form of adoptive cell therapy, where immune cells are either collected from the patient or a donor, then specially processed or manufactured in the laboratory before being infused back into the patient. The goal is to provide the patient with T cells—a type of white blood cell—that are specifically trained to recognize and attack BK virus-infected cells, without attacking the transplanted organ.^[3][8]

There are several approaches to creating these virus-specific T cells. In one method, T cells are isolated from a healthy donor who has natural immunity to BK virus. These cells are then expanded in the laboratory to increase their numbers and activated to enhance their ability to recognize BK virus proteins. The processed cells are then infused into the transplant patient, where they can seek out and destroy cells infected with the virus. Because these T cells are specifically directed against viral targets, they should not increase the risk of organ rejection, which is directed against different targets on the transplanted tissue.^[8]

Another approach involves identifying and isolating the patient’s own virus-specific T cells, which may be present but insufficient in number or function due to the immunosuppressive medications. These cells are then expanded and activated in the laboratory before being returned to the patient in much larger numbers. Early clinical trials have shown encouraging results, with some patients experiencing significant reductions in viral load and stabilization of kidney function after receiving virus-specific T cell therapy. The treatment is still considered experimental and is primarily available at specialized transplant centers participating in research studies.^[8][10]

The major advantages of virus-specific T cell therapy include its targeted approach and the potential to avoid the problems associated with reducing immunosuppression. However, the therapy is complex to produce, expensive, and not yet widely available. Clinical trials are ongoing to determine the optimal cell dose, timing of treatment, and long-term safety profile. Early studies have generally shown good safety, with the main side effects related to the infusion itself, such as fever or chills, which are typically mild and temporary.

Where Trials Are Happening

Clinical trials for BK virus treatments are being conducted at major transplant centers around the world. In the United States, research is ongoing at institutions including the Medical University of South Carolina and other academic medical centers with large transplant programs. International studies are also being conducted in Europe, including the United Kingdom, as well as in Australia where significant research on virus-specific T cell therapy has been pioneered at centres such as QIMR Berghofer Medical Research Institute in Queensland.^[3][8]

Patients interested in participating in clinical trials for BK virus treatment should discuss this option with their transplant team. Eligibility typically depends on factors such as the viral load in blood, evidence of kidney damage, time since transplant, and whether the patient has already tried standard treatments. Some trials are specifically for patients who have not responded to reduction of immunosuppression, while others may be testing preventive strategies in all transplant recipients.

Most Common Treatment Methods

• Reduction of Immunosuppression
  • Lowering doses of calcineurin inhibitors such as tacrolimus or cyclosporine to allow immune recovery
  • Switching to mTOR inhibitors like sirolimus or everolimus as alternative immunosuppression
  • Carefully balancing viral control against risk of organ rejection through close monitoring
  • Gradual dose adjustments based on viral load measurements and kidney function tests
• Intensive Screening and Monitoring
  • Monthly blood and urine testing for BK viral DNA during the first six months post-transplant
  • Quarterly screening from six months to two years after transplantation
  • Early intervention when virus is detected before kidney damage develops
  • Regular assessment of kidney function through blood tests and occasional biopsies
• Leflunomide Therapy
  • Medication with both immunosuppressive and antiviral properties
  • Inhibits viral replication through interference with metabolic pathways
  • Used in some transplant centers with variable success rates
  • Requires monitoring for side effects including liver function abnormalities
• Intravenous Immunoglobulin (IVIG)
  • Infusion of concentrated antibodies from healthy donors
  • Provides passive immunity against common BK virus strains
  • Used for both treatment of active infection and potential prevention
  • Generally well-tolerated with monitoring for infusion reactions
• Virus-Specific T Cell Therapy (Experimental)
  • Adoptive transfer of T cells specifically targeting BK virus
  • Cells may come from patient’s own blood or from matched donors
  • Expanded and activated in laboratory before infusion
  • Available primarily in clinical trials at specialized centers
  • Shows promise for refractory cases not responding to standard treatment
• Supportive Care
  • Maintaining adequate hydration to support kidney function
  • Managing symptoms such as blood in urine or pain if present
  • Regular follow-up appointments to monitor treatment response
  • Patient education about signs of rejection or worsening infection